UMC’s quiet surge looks like the market catching up to a recovery that is already underway. The cleanest proof is not a rumor or a macro narrative; it is May net sales rising 17.78% year over year, right after management guided Q2 wafer shipments to grow by high-single digits sequentially. That is exactly what a real cyclical turn looks like in a foundry name: utilization improves first, shipments follow, and the stock moves before the broad crowd is comfortable. We think this rally is justified because the operating data now supports it.
The most important number here is that 17.78% May sales growth. UMC reported May 2026 net sales of NT$22.944 billion, up from a year ago and slightly above April’s NT$22.664 billion, while January through May sales climbed 9.05% year over year to NT$106.646 billion. That matters because it turns the recovery story from a hope into a measurable trend. A one-day stock move can be noise; accelerating monthly revenue is not.
Management’s own operating outlook reinforces that signal. In Q1, wafer shipments already rose 2.7% sequentially and fab utilization improved to 79%, then the company said Q2 wafer shipments should rise by high-single digits sequentially. That is the kind of setup bulls want in a mature-node foundry: volume is improving before the income statement fully reflects it. UMC is not being priced on a distant turnaround anymore; it is being repriced on evidence that demand is broadening now.
The quality of that recovery also looks better than a simple low-end inventory refill. UMC said 22nm revenue reached 14% of total wafer revenue in Q1, while 22/28nm combined reached 34%, showing that the mix is leaning into stronger specialty nodes rather than just commodity capacity. Margins held up too, with Q1 gross margin at 29.2% and operating margin at 18.5%, which helps explain why the TickerSpark Score is strong where it counts: 85 for Profitability, 100 for Financial Health, and 100 for Momentum. Even at a richer 39.9x trailing earnings multiple, UMC is not trading like a broken cyclical. Against peers, that is not outrageous either: GFS sits at 51.09x earnings with just 0.6% revenue growth and an 11.4% net margin, while UMC posts a 20.8% net margin.
The pushback is real enough. Trailing growth still looks mixed, with reported revenue growth at 2.3%, EPS growth down 12.1%, and net income growth down 11.6%, so anyone calling the stock expensive at 39.9x earnings is not making that up. UMC also acknowledged slight ASP pressure in Q1, partly from a higher 8-inch mix, and one strong month does not erase the fact that Q1 revenue was down sequentially.
That said, the market is paying for direction, not for the last soft patch. The combination of 79% utilization, high-single-digit Q2 shipment guidance, and a 17.78% year-over-year jump in May sales is stronger evidence than the backward-looking growth prints. Consensus still reads as a Hold, with 4 buys, 8 holds, and 3 sells, which is exactly why this setup still has room: the fundamentals are improving faster than the crowd’s comfort level.
We would treat UMC as a momentum-backed recovery name rather than a deep-value semiconductor bet. The stock has already massively outperformed, up 207.1% year to date versus 33.6% for the technology sector, so chasing blindly after an 11.7% daily move is not the point. The point is that the move now has a fundamental spine, and that keeps us constructive.
What we would watch next is simple: the July 6 monthly sales release needs to confirm that May was not a one-off burst. If June sales keep the year-over-year acceleration intact, the bull case strengthens because the shipment guidance and revenue trend will be lining up in real time. If that momentum breaks immediately, the valuation becomes much harder to defend. Until then, we think the market is finally pricing a real foundry recovery in UMC, and we would stay on that side of the trade.
